Drug Research
Drug Discovery & Development

Ipsen, MD Anderson form bench-to-bedside cancer drug development partnership

Published 30 May 2018

Ipsen has entered into a global licensing and joint development agreement with and The University of Texas MD Anderson Cancer Center for a pre-clinical oncology drug candidate discovered by researchers in the latter’s Institute for Applied Cancer Science (IACS).

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Ipsen research & development executive vice president and chief scientific officer Alexandre Lebeaut said: “We are very pleased to partner with the IACS at the MD Anderson Cancer Center whose reputation in scientific excellence and clinical care in Oncology is outstanding.

“Through this collaboration, we aim to synergize IACS’ scientific expertise with Ipsen’s drug development capabilities to deliver innovative therapies more rapidly to patients in need, and advance patient care in Oncology”.

MD Anderson and Ipsen also will collaborate to conduct additional pre-clinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications.

The detailed financial terms of the agreement, including development and commercial milestones and royalties, have not been disclosed.

MD Anderson chief medical executive Stephen Hahn said: “We believe this partnership has the potential to deliver a new therapeutic option to our patients.

“This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most.”

Source: Company Press Release.